drugset / Trial / NCT02487823
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in combination with daily bicalutamide and LH-RH agonists to men with non castrate metastatic prostate cancer.
Timeline
- Start
- 2014-10
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 60 mg | Oral |
| Subject | Buparlisib | Small molecule | 80 mg | Oral |
| Subject | Buparlisib | Small molecule | 100 mg | Oral |
| Background | Bicalutamide | Other / unclassified | — | — |
| Background | suprefact | Unknown | — | — |